SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
 

Stoke Therapeutics, Inc.

(Name of Issuer)
 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)
 

86150R107

(CUSIP Number)
 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 86150R107

13G/APage 2 of 7 Pages

 

 

1

NAME OF REPORTING PERSON

 

Lynx1 Capital Management LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,956,918

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,956,918

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,956,918

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.6%

12

TYPE OF REPORTING PERSON

PN

         

 

 

 

CUSIP No. 86150R107

13G/APage 3 of 7 Pages

 

1

NAME OF REPORTING PERSON

 

Weston Nichols

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,956,918

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,956,918

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,956,918

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.0%

12

TYPE OF REPORTING PERSON

IN

         

 

 

CUSIP No. 86150R107

13G/APage 4 of 7 Pages

 

Item 1(a). Name of Issuer:
   
  Stoke Therapeutics, Inc. (the “Issuer”)

 

Item 1(b). Address of Issuer’s Principal Executive Offices:
   
 

45 Wiggins Ave.

Bedford, MA 01730

 

Item 2(a). Name of Person Filing:
   
  This statement is filed by:  

 

  (i) Lynx1 Capital Management LP (the “Investment Manager”), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the “Lynx1 Fund”), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Lynx1 Fund; and
     
  (ii) Mr. Weston Nichols (“Mr. Nichols”), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Lynx1 Fund.

 

  The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
   
  The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

 

Item 2(b). Address of Principal Business Office:
   
 

Lynx1 Capital Management LP

151 Calle de San Francisco

Suite 200, PMB 1237

San Juan, PR 00901-1607

   
 

Weston Nichols

c/o Lynx1 Capital Management LP

151 Calle de San Francisco

Suite 200, PMB 1237

San Juan, PR 00901-1607

   
Item 2(c). Place of Organization:
   
 

Investment Manager – Delaware

Mr. Nichols – United States of America

 

 

CUSIP No. 86150R107

13G/APage 5 of 7 Pages

 

Item 2(d). Title of Class of Securities:
   
  Common stock, $0.0001 par value per share (the “Common Stock”)

 

Item 2(e). CUSIP Number:
   
  86150R107

 

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

 

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

  (g) o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

  (h) ¨

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

 

  (i) ¨

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution:                                                                                  

 

 

CUSIP No. 86150R107

13G/APage 6 of 7 Pages

 

Item 4. Ownership:
   
  The information required by Items 4(a) – (c)  is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each  Reporting Person.  
   
  The percentages set forth herein are calculated based upon 44,653,782 shares of Common Stock outstanding as of October 30, 2023, as reported in the Issuer's Quarterly Report on 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 7, 2023.  

 

Item 5. Ownership of Five Percent or Less of a Class:
   
  Not applicable.

 

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
   
  See Item 2. The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.  

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
   
  Not applicable.

 

Item 8. Identification and Classification of Members of the Group:
   
  Not applicable.

 

Item 9. Notice of Dissolution of Group:
   
  Not applicable.

 

Item 10. Certification:
   
  By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

CUSIP No. 86150R107

13G/APage 7 of 7 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

 

Date:  February 14, 2024  
 

Lynx1 capital management lp

By: Lynx1 Capital Management GP LLC, its general partner

   
  By:  /s/ Weston Nichols                              
  Name:  Weston Nichols   
  Title:    Sole Member
   
   
   
   
  /s/ Weston Nichols
  WESTON NICHOLS

 

Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Stoke Therapeutics Charts.
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Stoke Therapeutics Charts.